Huntsworth announces Liz McKee Anderson as upcoming Independent Director alongside Andy Boland as Senior Independent Director

– UK, London – Huntsworth PLC (LSE:HNT), the international healthcare communications and public relations group, announced a number of changes to the membership of its Board of Directors and Committees, all to be effective from 1 January 2018.

Liz McKee Anderson will join the Board of Directors of Huntsworth plc as an independent non-executive director.

Liz has extensive experience in the pharmaceuticals industry, notably having held a number of senior executive roles at Johnson & Johnson. Since April 2017, Liz has been a Board Director of Bavarian Nordic A/S, a biotechnology company listed on the Danish stock exchange. Liz is also an Independent Board Director of Revolution Medicines, Inc. She holds a number of other positions in both commercial and non-profit spheres, including the Wistar Institute. Liz holds an MBA from Loyola University and has a degree in Engineering. Liz will be a member of the Company’s Audit Committee.

Derek Mapp, Chairman of Huntsworth said: “I am delighted that we have managed to recruit a very high calibre individual to the Board with extensive experience in the pharmaceutical and biotechnology industries. These industries are of increasing importance to Huntsworth as can be seen with the growth and significance of the Huntsworth Health business.”

Andy Boland will be appointed as Huntsworth’s Senior Independent Director. Andy has been a director of Huntsworth plc since 11 August 2014, has previously served as the chair of the Audit Committee and remains as a member of both the Audit and Nomination Committees.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.